Abstract 391P
Background
Since 2017, the combination of CDK4/6 inhibitors and endocrine therapy has been the standard first-line treatment for patients diagnosed with hormone-positive/HER2-negative metastatic breast cancer (mBC) in Denmark. Previous analyses, based on randomized phase III studies, have shown that the clinical benefit remains after CDK4/6i dose reduction, but analyses may have been susceptible to immortal time bias.
Methods
This real-world cohort study is based on electronic health records from 695 patients from the capitol region of Denmark who initiated first-line treatment for mBC with CDK4/6i between May 2017 and October 2022. We used landmark Kaplan-Meier estimates and Cox regression to examine the association of dose reduction with treatment duration and overall survival. Patients were categorized based on dose reduction from the recommended dose prior to the landmark, defined at 3 months after initiation of treatment. Hazard ratios were adjusted for CDK4/6i agent, age, comorbidity, BMI, LDH > ULN, ECOG performance status and visceral metastases.
Results
A total of 530 patients were eligible for inclusion in the landmark analysis and 198 (37%) were categorized into the dose reduction group. Patients with dose reduction were significantly older and more had received prior endocrine therapy. Dose reduction was significantly associated with overall survival and shorter treatment duration, 39.6 vs 55.6 months (95%CI: 35.5-NE vs 49.9-NE) and 19.6 vs. 30.3 months, respectively. Adjusted hazard ratio for death was 1.49 for patients with dose reduction (95% CI: 1.01-2.22).
Conclusions
Dose reduction of CDK4/6i within the first 3 months was associated with significantly higher mortality and shorter treatment duration. These findings contrast previous analyses that have shown no effect of dose reduction on treatment efficacy. Consideration of immortal time bias in this study may be a decisive reason for the disparate findings. Table: 391P
Characteristic | Dose reduction, N = 1981 | Full dose, N = 3321 | p-value |
CDK4/6i | 0.14 | ||
Abemaciclib | 48 (24%) | 99 (30%) | |
Palbociclib | 104 (53%) | 145 (44%) | |
Ribociclib | 46 (23%) | 88 (27%) | |
Age | 72 (63, 78) | 67 (58, 75) | <0.001 |
Primary metastatic | 51 (26%) | 102 (31%) | 0.2 |
Prior endocrine treatment | 144 (73%) | 199 (60%) | 0.003 |
Charlson Comorbidity Index2 | 0.3 | ||
0 | 145 (73%) | 256 (77%) | |
1 | 31 (16%) | 52 (16%) | |
2+ | 22 (11%) | 24 (7%) | |
Visceral metastasis3 | 41 (55%) | 41 (55%) | >0.9 |
ECOG Performance Status3 | 0.2 | ||
0 | 30 (50%) | 45 (66%) | |
1 | 25 (42%) | 20 (29%) | |
2 | 5 (8.3%) | 3 (4.4%) | |
Unknown | 15 | 7 |
1n (%); Median (IQR). 2Modified to exclude solid tumors. 3Manual review of a random sample of 75 patients in each group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
349P - The influence of diabetes on taxane-induced neurotoxicity and quality of life in breast cancer patients
Presenter: Erika Cimbro
Session: Poster session 03
350P - Quality of life data on sexual relations in early breast cancer patients
Presenter: María Garrido
Session: Poster session 03
351TiP - EORTC BCG 1984 – NOBLE: Noeoadjuvant olaparib and durvalumab for patients with BRCA-associated triple-negative breast cancer
Presenter: Emanuel Buhrer
Session: Poster session 03
352TiP - Neoadjuvant chemo-immunotherapy plus/minus fasting-like approach in stage II-III triple-negative breast cancer patients: The phase II randomized BREAKFAST-2 trial
Presenter: Claudio Vernieri
Session: Poster session 03
355P - Reduction of anthracycline use with a combined imaging and pathology prediction model in the neoadjuvant I-SPY2 trial
Presenter: Angela DeMichele
Session: Poster session 03
356P - Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study
Presenter: Soumya Gottipati
Session: Poster session 03
357P - Prediction of pathologic response to neoadjuvant chemotherapy (NAC) using diffuse optical breast scanner (DOB-Scan) in patients with locally advanced breast cancer (LABC)
Presenter: Phuong Thao Nguyen
Session: Poster session 03
358P - Major adverse cardiovascular event outcomes of adjuvant taxane + anthracycline versus taxane-based chemotherapy in older adults with triple-negative breast cancer: A SEER-Medicare study
Presenter: Savannah Roy
Session: Poster session 03